The association of body mass index with tumor aggression among men undergoing radical prostatectomy
- PMID: 38262868
- DOI: 10.1016/j.urolonc.2023.12.013
The association of body mass index with tumor aggression among men undergoing radical prostatectomy
Abstract
Objectives: To evaluate the association of preoperative body mass index (BMI) on adverse pathology in peripheral (PZ) and transition zone (TZ) tumors at time of prostatectomy for localized prostate cancer.
Methods: Clinical and pathologic characteristics were obtained from up to 100 consecutive prostatectomy patients from 10 prostate surgeons. BMI groups included normal (18.5-24.9), overweight (25-29.9) and obese (> 29.9). "Aggressive" pathology was defined as the presence of Grade Group (GG) 3 or higher and/or pT3a or higher. Pathologic characteristics were evaluated for association with BMI using univariate analyses. Our primary outcome was the association of BMI with adverse pathology, which was assessed using logistic regression accounting for patient age. We hypothesized that obese BMI would be associated with aggressive TZ tumor.
Results: Among 923 patients, 140 (15%) were classified as "normal" BMI, 413 (45%) were "overweight", and 370 (40%) were "obese." 474 patients (51%) had aggressive PZ tumors while 102 (11%) had aggressive TZ tumors. "Obese" BMI was not associated with aggressive TZ tumor compared to normal weight. Increasing BMI group was associated with overall increased risk of aggressive PZ tumor (HR 1.56 [95CI 1.04-2.34]; P = 0.03). Among patients with GG1 or GG2, increasing BMI was associated with presence of pT3a or higher TZ tumor (P = 0.03).
Conclusions: Increased BMI is associated with adverse pathology in PZ tumors. TZ adverse pathology risk may be increased among obese men with GG1 or GG2 disease, which has implications for future studies assessing behavioral change among men whose tumors are actively monitored.
Keywords: Obesity; Pathologic outcome; Peripheral; Prostatic neoplasms; Transition zone.
Copyright © 2023. Published by Elsevier Inc.
Conflict of interest statement
Declaration of competing interest The authors do not report any conflicts of interest.
Similar articles
-
Hormonal contraceptives for contraception in overweight or obese women.Cochrane Database Syst Rev. 2016 Aug 18;2016(8):CD008452. doi: 10.1002/14651858.CD008452.pub4. Cochrane Database Syst Rev. 2016. PMID: 27537097 Free PMC article.
-
Hormonal contraceptives for contraception in overweight or obese women.Cochrane Database Syst Rev. 2013 Apr 30;(4):CD008452. doi: 10.1002/14651858.CD008452.pub3. Cochrane Database Syst Rev. 2013. Update in: Cochrane Database Syst Rev. 2016 Aug 18;(8):CD008452. doi: 10.1002/14651858.CD008452.pub4. PMID: 23633356 Updated.
-
Diet, physical activity and behavioural interventions for the treatment of overweight or obese children from the age of 6 to 11 years.Cochrane Database Syst Rev. 2017 Jun 22;6(6):CD012651. doi: 10.1002/14651858.CD012651. Cochrane Database Syst Rev. 2017. PMID: 28639319 Free PMC article.
-
Laparoscopic and robotic-assisted versus open radical prostatectomy for the treatment of localised prostate cancer.Cochrane Database Syst Rev. 2017 Sep 12;9(9):CD009625. doi: 10.1002/14651858.CD009625.pub2. Cochrane Database Syst Rev. 2017. PMID: 28895658 Free PMC article.
-
Systematic review and economic modelling of the relative clinical benefit and cost-effectiveness of laparoscopic surgery and robotic surgery for removal of the prostate in men with localised prostate cancer.Health Technol Assess. 2012;16(41):1-313. doi: 10.3310/hta16410. Health Technol Assess. 2012. PMID: 23127367 Free PMC article.
Cited by
-
Complications of Prostate Cancer Treatment: Open Issues.J Clin Med. 2024 May 24;13(11):3090. doi: 10.3390/jcm13113090. J Clin Med. 2024. PMID: 38892801 Free PMC article.
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Medical